Medical AI Web Services in the U.S. (Series 1)

Part 1: The Big Picture and Five Questions

June 16, 2026 · Shishido & Associates
Part 1: The Big Picture and Five Questions

In the United States, medical AI web services built around generative AI and large language models (LLMs) are rapidly entering the practical-use stage.
In this series (five parts, free of charge), we will organize the big picture, specific services, the market and its challenges, and IP/licensing strategies,
and answer the questions raised here in the final installment.

Fig.: the spread of medical-AI web services in the U.S. (image).
Fig.: the spread of medical-AI web services in the U.S. (image).図：AI作図 © 宍戸＆アソシエーツ（Gemini作成）／データ出典: 本連載イメージ

Main Categories of Medical AI Web Services

  • Ambient clinical documentation (automatically generating draft medical records from conversations between physicians and patients)
  • Patient-facing agents (symptom consultation, pre-visit triage, medication support)
  • Clinical decision support / evidence search (answers based on the latest literature)
  • Imaging triage (detection and notification of emergency findings such as stroke and pulmonary embolism)
  • Pathology and genomics (analysis of cancer pathology images and integration of molecular information)
Fig.: the five main categories of medical-AI web services.
Fig.: the five main categories of medical-AI web services.図：宍戸＆アソシエーツ作成（matplotlib）

Why Is the U.S. Ahead?

Abundant venture capital, the development of regulatory pathways including the FDA's SaMD (Software as a Medical Device),
discussions on reimbursement, and room for integration with the vast EHR (electronic health record) infrastructure (such as Epic)—
all of these are driving implementation and adoption.

Fig.: the five issues this series examines.
Fig.: the five issues this series examines.図：宍戸＆アソシエーツ作成（matplotlib）

Five Issues This Series Will Examine (Framing the Problem)

  1. Clinical value: Which services genuinely improve the quality and efficiency of healthcare?
  2. Market and revenue: What is the reality of the market size and revenue models (subscription / usage-based / reimbursement)?
  3. Regulation and liability: How should FDA SaMD, HIPAA, and medical malpractice liability be designed?
  4. Web development: What are the technical and security challenges of web applications that handle PHI (Protected Health Information)?
  5. IP and licensing: Why is a strategy that encompasses not only patents but also software program licensing essential?

Parts 2 through 4 will explore these in concrete detail, and Part 5 will answer these questions.

Key Point: These five issues are not independent. A business can only succeed with a trinity of clinical value, regulatory compliance, and IP/licensing. If even one is missing, even good technology cannot survive in the market.

Note: This series is a summary compiled by the editorial team. Specific figures and the latest situation vary depending on the source, and we will update them from time to time.

Fig.: the key point — the trinity of clinical × regulation × IP.
Fig.: the key point — the trinity of clinical × regulation × IP.図：AI作図 © 宍戸＆アソシエーツ（Gemini作成）／データ出典: 本連載イメージ
Other languages: Deutsch · 日本語

📄 Full-series PDF (monthly-member benefit)

The whole series (5 parts) as a single PDF. As a monthly member, you can download it.

Become a member

📚 This series (all 5 parts)

← scroll horizontally for all parts →

Part 1: The Big Picture and Five Questions ▶ This part Part 1: The Big Picture and Five Questions Part 2: The Current State of Representative Services (Ambient Documentation, Triage, Pathology, and More) Part 2: The Current State of Representative Services (Ambient Documentation, Triage, Pathology, and More) Part 3: Market Size, Challenges, and Considerations for Web App Development Part 3: Market Size, Challenges, and Considerations for Web App Development Part 4: IP Strategy — Patents and Software Licensing (Pitfalls Such as AGPL) Part 4: IP Strategy — Patents and Software Licensing (Pitfalls Such as AGPL) Part 5: Conclusion — Answering the Questions Raised in Part 1 Part 5: Conclusion — Answering the Questions Raised in Part 1

More articles

Why Only a "Handful of Companies" Reaped Enormous Profits from mRNA Vaccines —— How Patent Strategy Decided Pharmaceutical Supremacy [Paid]
Jun 16, 2026
Why Only a "Handful of Companies" Reaped Enormous Profits from mRNA Vaccines —— How Patent Strategy Decided Pharmaceutical Supremacy [Paid]
 Playing the piano pedal with your head — inside the bFaaaP Open Source Project
Jun 16, 2026
Playing the piano pedal with your head — inside the bFaaaP Open Source Project